Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Wegovy weight loss pen is a pre-filled, once-weekly injection of semaglutide, a GLP-1 receptor agonist that reduces appetite by mimicking a gut hormone your body releases after eating. It is a prescription-only medicine licensed in the UK for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition. A prescriber assesses whether it is clinically suitable before treatment begins. If you have looked into how Wegovy injections work in practice, this page covers the pen itself: its design, how to use it, what to realistically expect, and when to get help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Wegovy pen is a single-use, disposable auto-injector. Each pen contains four weekly doses — or, with the newer 7.2 mg pen approved by the MHRA in April 2026, a single dose in one pre-set device. You do not load a cartridge, attach a needle separately, or dial a dose. The needle is covered and retracts automatically after injection, which most people find far less daunting than it sounds beforehand.
Semaglutide is the active medicine inside, and if you want to understand how semaglutide weight loss injections work in more depth, that page covers the mechanism and what to expect from treatment. It is a GLP-1 receptor agonist, meaning it binds to receptors in the gut and brain that are normally activated by the hormone GLP-1, released when you eat. The result is a combination of effects: your stomach empties more slowly, you feel full sooner, and the hunger signals reaching your brain quieten down. Over time, most people find they are genuinely less interested in food rather than just trying harder to resist it.
One quick check worth doing every time: before you inject, hold the pen up to the light and confirm the liquid inside looks clear and colourless. If it looks cloudy, discoloured, or contains visible particles, do not use that pen and contact your prescriber. It takes ten seconds and matters.
The three recommended injection sites are the abdomen, the front of the thigh, and the upper arm. Rotate the site each week, same body region is fine, but shift the exact spot to give the skin time to recover. Injecting into scar tissue or broken skin should be avoided.
The technique is straightforward. Clean the site, pinch the skin gently if you are using the abdomen, press the pen firmly against the skin, and hold the button down until the injection is complete. Your Patient Information Leaflet walks through every step in detail, and your prescriber will confirm technique with you. The needle is fine enough that many people describe the sensation as a mild sting at most. Detailed guidance on taking Wegovy correctly covers timing, what to do if you miss a dose, and storage, all of which are best confirmed with your prescriber and the leaflet rather than generalised advice online.
Storage matters too. Wegovy pens are kept refrigerated at 2 to 8°C. There is a limited window during which an unrefrigerated pen remains usable; the exact duration is in the leaflet because it varies by pen format, and citing a number here could mislead you if your device differs.
The side-effect profile is dominated by gastrointestinal symptoms: nausea is the most frequently reported, followed by constipation, diarrhoea, vomiting, and indigestion. These tend to be most noticeable in the days after starting or moving to a higher dose, and for many people they ease considerably once the body adjusts. Eating smaller meals and avoiding very fatty or rich food during the first weeks helps. Fatigue and headache are also reported, particularly early on.
Serious side effects are rarer. Pancreatitis is one the MHRA has flagged specifically for GLP-1 medicines: severe stomach pain that persists and may spread to the back, with or without vomiting, needs urgent medical attention rather than a wait-and-see approach. Gallbladder problems, allergic reactions, and significant mood changes are also listed as reasons to seek help promptly. The NHS medicines page for semaglutide sets out the full side-effect picture clearly, and if you experience something unexpected, you can report it directly via the MHRA Yellow Card scheme.
A note on a symptom some people mention but do not always connect to their pen: a metallic or altered taste in the mouth. It is not listed as a common side effect in the trial data, but it does come up. There is a page covering that altered taste after a Wegovy injection if it is something you have noticed.
Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The licence does not extend to people who are pregnant, breastfeeding, or trying to conceive; it is also not licensed for use under 18. Certain medical histories, including past pancreatitis and some thyroid conditions, require careful prescriber assessment.
On the NHS, Wegovy is recommended under NICE guidance TA875 for use within specialist weight management services, and waiting lists can be long. Private treatment through a regulated pharmacy does not require a referral, though clinical assessment is still required for every patient before a prescription is issued, that is not optional, it is the law.
If you are weighing up the cost side of things, our guide to Wegovy pricing in the UK explains what legitimate private treatment typically costs and what to be cautious about with very low prices. For anything else, speak to our prescribers through a free consultation, a real clinician reads your answers and responds the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.